NewEdge Advisors’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
Other funds holding MYGN
NewEdge Advisors's MYGN Position: Q3 2026 in Review
NewEdge Advisors sold out of Myriad Genetics (MYGN) in Q3 2026, closing a stake of 52,385 shares — an estimated $299K sold.
NewEdge Advisors first reported a position in MYGN in Q2 2021 and held it in 3 quarters. The position peaked at $299K in Q2 2026. 176 funds tracked by Wall St. Rank hold MYGN as of Q3 2026.
- NewEdge Advisors reported no remaining Myriad Genetics position as of Q3 2026 after selling out during the quarter.
- NewEdge Advisors sold 52,385 Myriad Genetics shares in Q3 2026, an estimated $299K.
- NewEdge Advisors first reported a position in Myriad Genetics in Q2 2021 and held it in 3 quarters.
- NewEdge Advisors's Myriad Genetics position peaked at $299K in Q2 2026.
- 176 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2026.
Based on NewEdge Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.